8.92Open8.92Pre Close0 Volume4 Open Interest42.50Strike Price0.00Turnover0.00%IV8.87%PremiumDec 20, 2024Expiry Date4.73Intrinsic Value100Multiplier3DDays to Expiry4.19Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet